Compare LyondellBasell Industries NV (LYB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Moderna, Inc. — how do they compare? LyondellBasell Industries NV trades at $60.45 (market cap $19.49B), while Moderna, Inc. trades at $214.64 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Moderna, Inc. for 59 Days on average.
| LYB | MRNA | |
|---|---|---|
Market Cap | $19.49B | $78.65B |
Volume | 6,033,396 | 37,373,437 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $203.46 |
52-Week Low | $42.28 | $22.36 |
Typical Hold Time | 87 Days | 59 Days |
Enterprise Value | $31.08B | $74.80B |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings show volatility, with a Q2 2026 beat but a net loss for 2025. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, though 2026 projects a slight recovery. The stock offers a dividend, but news highlights concerns over dividend sustainability amid sector challenges.
Outlook is cautious; analyst consensus is split with a $69.38 price target suggesting upside, but profitability metrics are weak. Key risks include persistent negative margins, high debt, and chemical sector cyclicality. Investment opportunity hinges on operational turnaround and market recovery, but near-term headwinds prevail.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
